G0S2 and metabolic dysfunction-associated steatotic liver disease: Further obtained structural information of this protein and its interactions with ATGL will aid in the future development of drugs to inhibit the G0S2 proteins binding to adipose triglyceride lipase and create a possible effective therapy against NAFLD.